```html

Zollinger‑Ellison Syndrome (Gastrinoma)

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more tumors called gastrinomas develop in the pancreas, duodenum, or nearby lymph nodes. These tumors secrete excessive amounts of gastrin, a hormone that stimulates the stomach lining to produce large volumes of acid. The resulting hyperacidity leads to severe peptic ulcers, diarrhea, and malabsorption.

Who it affects

• Adults most commonly diagnosed between ages 30 and 60.
• Both men and women are affected, with a slight male predominance (≈55% male).
• Approximately 20–25% of patients have a hereditary form associated with Multiple Endocrine Neoplasia type 1 (MEN‑1).

Prevalence

• Overall incidence is about 0.5–2 cases per million people per year.<sup>[1]</sup>
• Because many gastrinomas are small and asymptomatic, the true prevalence may be slightly higher.

Symptoms

Symptoms arise from excessive gastric acid and from the tumor itself. They can vary widely, so clinicians consider a combination of findings when suspecting ZES.

Gastro‑intestinal symptoms

• Recurrent or refractory peptic ulcers – often multiple, located beyond the duodenum (e.g., jejunal ulcers).
• Abdominal pain – crampy or burning, may worsen after meals.
• Diarrhea – watery, sometimes greasy; occurs in up to 70% of patients due to acid inactivation of pancreatic enzymes.
• Steatorrhea (fatty stools) – result of malabsorption of fats.
• Nausea & vomiting – especially after large meals.
• Weight loss – from chronic malabsorption and poor intake.

Systemic / hormonal symptoms

• Gastrin‑related flushing – occasional facial flushing after meals.
• Hypokalemia – low potassium due to chronic diarrhea.
• Bone pain / osteopenia – chronic acid load can affect calcium balance.

Symptoms related to tumor location

• If the gastrinoma is in the pancreas: possible back pain or a palpable abdominal mass.
• If in the duodenum or lymph nodes: rarely produces a distinct mass but may cause localized discomfort.

Causes and Risk Factors

ZES is fundamentally a neuroendocrine tumor (NET) that overproduces gastrin. The underlying cause can be sporadic or hereditary.

Primary causes

• Sporadic gastrinoma – ~75–80% of cases. The exact trigger for malignant transformation is unknown.
• MEN‑1 syndrome – Autosomal‑dominant mutation in the MEN1 tumor suppressor gene. Up to 25% of ZES patients have MEN‑1, and 30–50% of MEN‑1 patients develop gastrinomas.
• Rare genetic conditions – Mutations in CDC73 (hyperparathyroidism‑jaw tumor syndrome) have been reported.

Risk factors

• Family history of MEN‑1 or other endocrine tumors.
• Age >30 years (most diagnoses occur after this age).
• Previous history of gastric ulcer disease (often a clue rather than a cause).

Diagnosis

Because symptoms overlap with common ulcer disease, clinicians use a stepwise approach that combines biochemical testing, imaging, and sometimes endoscopic evaluation.

1. Biochemical testing

• Fasting serum gastrin level – a level > 1000 pg/mL (≈10× upper limit) is highly suggestive. Even modest elevations (≥200 pg/mL) are significant if accompanied by low gastric pH.
• Secretin stimulation test – administration of secretin causes a paradoxical rise in gastrin in ZES (≥120 pg/mL rise). This test has a sensitivity > 90% and is considered the gold standard when fasting gastrin is equivocal.<sup>[2]</sup>
• Gastric pH measurement – an intragastric pH <2 confirms acid hypersecretion.

2. Imaging studies

• Multiphasic contrast‑enhanced CT scan of the abdomen – detects tumors ≥1 cm; evaluates for metastasis (liver, lymph nodes).
• Magnetic resonance imaging (MRI) with liver‑specific contrast – superior for hepatic metastases.
• Somatostatin receptor scintigraphy (Octreoscan) or 68Ga‑DOTATATE PET/CT – high sensitivity for small gastrinomas and metastatic disease.
• EUS (Endoscopic Ultrasound) – excellent for detecting pancreatic/duodenal lesions <1 cm.

3. Endoscopic evaluation

• Upper endoscopy (EGD) – identifies ulcer locations, assesses mucosal damage, and obtains biopsies to rule out H. pylori or malignancy.

4. Genetic testing (when indicated)

• Patients with a family history or features of MEN‑1 should undergo MEN1 gene sequencing.

Treatment Options

Therapy aims to control acid hypersecretion, remove or control tumor growth, and manage complications.

1. Acid suppression (first‑line)

• Proton pump inhibitors (PPIs) – high‑dose (e.g., omeprazole 60 mg daily or esomeprazole 40 mg daily) are the cornerstone. Most patients achieve symptom control within days.
• Histamine‑2 receptor antagonists (H2 blockers) – less effective alone but may be added for breakthrough symptoms.

2. Surgical management

• Curative resection – indicated for solitary, non‑metastatic gastrinomas <2 cm. Options include duodenotomy with tumor excision or pancreatic enucleation.
• Debulking surgery – for metastatic disease; reduces tumor burden and may lessen gastrin output.
• Liver metastasectomy or radiofrequency ablation – considered if hepatic lesions are limited.

3. Medical therapy for tumor control

• Somatostatin analogues (e.g., octreotide, lanreotide) – bind somatostatin receptors, reducing gastrin secretion and slowing tumor growth. Effective in both sporadic and MEN‑1‑related disease.
• Targeted agents – everolimus (mTOR inhibitor) and sunitinib (tyrosine‑kinase inhibitor) have FDA approval for advanced pancreatic NETs and can be used off‑label for gastrinomas.
• Chemotherapy – generally reserved for high‑grade, rapidly progressive disease; regimens may include streptozocin‑based combinations.

4. Radiologic/locoregional therapies

• Peptide receptor radionuclide therapy (PRRT) – 177Lu‑DOTATATE delivers targeted radiation to somatostatin‑receptor–positive tumors; shows promising control rates.
• Transarterial embolization (TAE) – for symptomatic hepatic metastases.

5. Lifestyle and supportive measures

• Small, frequent meals; avoid caffeine, alcohol, and spicy foods that can aggravate acid production.
• Calcium and vitamin D supplementation if malabsorption is present.
• Regular monitoring of bone density (DEXA scans) for osteopenia/osteoporosis.

Living with Zollinger‑Ellison Syndrome (gastrinoma)

Long‑term management is multidisciplinary. Below are practical tips for day‑to‑day living.

Medication adherence

• Take PPIs exactly as prescribed – usually 1–2 doses daily, 30 minutes before a meal.
• Carry a rescue dose of a PPI or H2 blocker for breakthrough heartburn.
• Set reminders (phone alarms, pillboxes) to avoid missed doses.

Dietary considerations

• Prefer low‑fat, low‑fiber meals that are easier to digest.
• Incorporate lean protein, cooked vegetables, and complex carbohydrates.
• Limit citrus, tomato‑based sauces, chocolate, and peppermint – all can stimulate acid.
• Stay hydrated; replace fluids lost through diarrhea with oral rehydration solutions.

Monitoring & follow‑up

• Quarterly blood work: fasting gastrin, electrolytes, liver function, and vitamin B12.
• Annual imaging (CT/MRI) to detect new lesions or metastasis.
• Endoscopic surveillance every 1–2 years, especially if ulcer disease persists.
• Bone density testing every 2–3 years.

Psychosocial support

• Join patient support groups (e.g., NET Connect, American Neuroendocrine Tumor Society).
• Consider counseling to cope with chronic disease stress.

When traveling

• Bring extra PPI supply and a written physician note.
• Research nearby hospitals that can manage a NET emergency.

Prevention

Because most gastrinomas are sporadic, primary prevention is limited. However, risk reduction strategies focus on early detection in high‑risk groups.

• Family screening – individuals with a first‑degree relative with MEN‑1 should undergo genetic counseling and periodic gastrin testing starting in adolescence.
• Routine surveillance for MEN‑1 patients – annual fasting gastrin levels and abdominal imaging, per Endocrine Society guidelines.
• Avoid chronic H. pylori infection – eradication does not prevent ZES but reduces the confounding risk of ulcer disease.

Complications

If left untreated or poorly controlled, ZES can lead to serious health problems.

• Severe, refractory peptic ulcer disease – may cause bleeding, perforation, or obstruction.
• Gastrointestinal bleeding – melena or hematemesis requiring transfusion or endoscopic therapy.
• Malabsorption & nutritional deficiencies – fat‑soluble vitamin (A, D, E, K) deficiencies, anemia, and weight loss.
• Electrolyte disturbances – recurrent diarrhea → hypokalemia, metabolic alkalosis.
• Osteoporosis / fractures – chronic acid load interferes with calcium balance.
• Metastatic disease – up to 50% of gastrinomas are malignant at diagnosis; liver metastases are the most common site and significantly affect prognosis.
• Reduced quality of life – chronic pain, frequent medication changes, and anxiety about cancer progression.

When to Seek Emergency Care

References

1. Mayo Clinic. Zollinger‑Ellison syndrome. https://www.mayoclinic.org
2. U.S. National Library of Medicine. Secretin stimulation test. PubMed PMID: 23627808
3. American Gastroenterological Association. Diagnosis and management of neuroendocrine tumors. https://www.gastro.org
4. Endocrine Society Clinical Practice Guideline: Screening and management of MEN‑1. https://www.endocrine.org
5. National Comprehensive Cancer Network (NCCN). Neuroendocrine and Paraganglioma Guidelines, Version 3.2024. PDF
6. World Health Organization. Classifications of Tumors of the Digestive System, 5th Edition. 2024.

```